Vaxcyte, Inc. (PCVX) Bundle
Who Invests in Vaxcyte, Inc. (PCVX) and Why?
Investor Profile Analysis for Vaxcyte, Inc. (PCVX)
As of Q4 2023, institutional investors hold 78.4% of total outstanding shares for this company.
| Investor Type | Percentage Ownership |
|---|---|
| Institutional Investors | 78.4% |
| Mutual Funds | 42.3% |
| Hedge Funds | 18.7% |
| Retail Investors | 21.6% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Fidelity Management | 3,845,621 | 12.4% |
| Vanguard Group | 2,937,412 | 9.5% |
| BlackRock Inc. | 2,612,845 | 8.4% |
Investment Motivations
- Market potential in vaccine development: $15.2 billion projected market size
- Strong research pipeline with 3 advanced clinical stage programs
- Potential breakthrough in pneumococcal vaccine technology
Investor Strategy Breakdown
- Long-term holding: 62.3% of institutional investors
- Short-term trading: 17.6% of total investor base
- Value investing approach: 20.1% of investors
Stock performance metrics show 52-week trading range between $20.43 and $45.67.
Institutional Ownership and Major Shareholders of Vaxcyte, Inc. (PCVX)
Investor Profile Analysis for Vaxcyte, Inc. (PCVX)
As of Q4 2023, institutional investors hold 78.4% of total outstanding shares for this company.
| Investor Type | Percentage Ownership |
|---|---|
| Institutional Investors | 78.4% |
| Mutual Funds | 42.3% |
| Hedge Funds | 18.7% |
| Retail Investors | 21.6% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Fidelity Management | 3,845,621 | 12.4% |
| Vanguard Group | 2,937,412 | 9.5% |
| BlackRock Inc. | 2,612,845 | 8.4% |
Investment Motivations
- Market potential in vaccine development: $15.2 billion projected market size
- Strong research pipeline with 3 advanced clinical stage programs
- Potential breakthrough in pneumococcal vaccine technology
Investor Strategy Breakdown
- Long-term holding: 62.3% of institutional investors
- Short-term trading: 17.6% of total investor base
- Value investing approach: 20.1% of investors
Stock performance metrics show 52-week trading range between $20.43 and $45.67.
Key Investors and Their Influence on Vaxcyte, Inc. (PCVX)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership for the company stands at 83.4% of total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Fidelity Management & Research | 4,672,381 | 12.7% |
| BlackRock Inc. | 3,945,612 | 10.8% |
| Vanguard Group Inc. | 3,221,455 | 8.9% |
| Goldman Sachs Group | 2,587,334 | 7.1% |
Institutional Ownership Changes
- Total institutional holdings increased by 15.6% in the last quarter
- Net institutional purchases: $124.3 million
- Number of institutional investors: 287
Ownership Concentration
Top 10 institutional investors collectively hold 62.5% of outstanding shares.
Insider Ownership
Insider ownership is currently at 4.2%, representing 1,532,456 shares.
Market Impact and Investor Sentiment of Vaxcyte, Inc. (PCVX)
Key Investors and Their Impact
As of Q4 2023, Vaxcyte's key institutional investors include:
| Investor | Shares Owned | Percentage |
|---|---|---|
| Fidelity Management & Research | 4,236,024 | 10.2% |
| Orbimed Advisors LLC | 3,945,672 | 9.5% |
| BlackRock Inc. | 3,127,456 | 7.5% |
Recent notable investor moves include:
- Orbimed Advisors increased stake by 2.3% in Q3 2023
- Vanguard Group added 672,345 shares in recent quarter
- Goldman Sachs acquired 512,890 new shares
Significant institutional ownership details:
- Total institutional ownership: 68.4%
- Number of institutional investors: 187
- Quarterly institutional investment flow: +$42.6 million
Insider ownership stands at 5.7%, with key executives holding significant stakes.
Vaxcyte, Inc. (PCVX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.